Ocular Therapeutix Files 8-K on Financials
Ticker: OCUL · Form: 8-K · Filed: Mar 11, 2024 · CIK: 1393434
| Field | Detail |
|---|---|
| Company | Ocular Therapeutix, Inc (OCUL) |
| Form Type | 8-K |
| Filed Date | Mar 11, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K, operations
Related Tickers: OCUL
TL;DR
OCUL filed an 8-K on March 11th detailing financial results and exhibits.
AI Summary
Ocular Therapeutix, Inc. filed an 8-K on March 11, 2024, reporting on its results of operations and financial condition, as well as filing financial statements and exhibits. The company, incorporated in Delaware, is based in Bedford, MA, and operates in the pharmaceutical preparations sector.
Why It Matters
This filing provides investors with crucial updates on Ocular Therapeutix's financial performance and operational status, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- OCULAR THERAPEUTIX, INC. (company) — Filer of the 8-K report
- March 11, 2024 (date) — Date of the earliest event reported
- Bedford, MA (location) — Principal executive offices location
- Delaware (location) — State of incorporation
FAQ
What specific financial information is being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on March 11, 2024.
What is the principal business of Ocular Therapeutix, Inc.?
The company is in the 'PHARMACEUTICAL PREPARATIONS' sector, SIC code 2834.
Where are Ocular Therapeutix, Inc.'s main offices located?
The principal executive offices are located at 15 Crosby Drive, Bedford, MA 01730.
What is the company's state of incorporation?
Ocular Therapeutix, Inc. is incorporated in Delaware.
Filing Stats: 507 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2024-03-11 16:10:50
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share OCUL The Nasdaq
Filing Documents
- tm248311d2_8k.htm (8-K) — 24KB
- tm248311d2_ex99-1.htm (EX-99.1) — 86KB
- 0001104659-24-032974.txt ( ) — 289KB
- ocul-20240311.xsd (EX-101.SCH) — 3KB
- ocul-20240311_lab.xml (EX-101.LAB) — 33KB
- ocul-20240311_pre.xml (EX-101.PRE) — 22KB
- tm248311d2_8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operations and Financial Condition. On March 11, 2024, Ocular Therapeutix, Inc. announced its financial results for the quarter and year ended December 31, 2023. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is furnished to comply with Item 2.02 of Form 8-K, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements
Financial Statements and Exhibits. (d) Exhibits: 99.1 Press Release of Ocular Therapeutix, Inc., dated March 11, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OCULAR THERAPEUTIX, INC. Date: March 11, 2024 By: /s/ Donald Notman Donald Notman Chief Financial Officer